Losartan prevents the elevation of blood pressure in adipose-PRR deficient female mice while elevated circulating sPRR activates the renin-angiotensin system.


Journal

American journal of physiology. Heart and circulatory physiology
ISSN: 1522-1539
Titre abrégé: Am J Physiol Heart Circ Physiol
Pays: United States
ID NLM: 100901228

Informations de publication

Date de publication:
01 03 2019
Historique:
pubmed: 15 12 2018
medline: 15 2 2020
entrez: 15 12 2018
Statut: ppublish

Résumé

Deletion of the prorenin receptor (PRR) in adipose tissue elevates systolic blood pressure (SBP) and the circulating soluble form of PRR (sPRR) in male mice fed a high-fat (HF) diet. However, sex differences in the contribution of adipose-PRR and sPRR to the regulation of the renin-angiotensin system (RAS) in key organs for blood pressure control are undefined. Therefore, we assessed blood pressure and the systemic and intrarenal RAS status in adipose-PRR knockout (KO) female mice. Blockade of RAS with losartan blunted SBP elevation in HF diet-fed adipose-PRR KO mice. ANG II levels were significantly increased in the renal cortex of HF diet-fed adipose-PRR KO female mice, but not systemically. HF diet-fed adipose-PRR KO mice exhibited higher vasopressin levels, water retention, and lower urine output than wild-type (WT) mice. The results also showed that deletion of adipose-PRR increased circulating sPRR and total hepatic sPRR contents, suggesting the liver as a major source of elevated plasma sPRR in adipose-PRR KO mice. To mimic the elevation of circulating sPRR and define the direct contribution of systemic sPRR to the regulation of the RAS and vasopressin, C57BL/6 female mice fed a standard diet were infused with recombinant sPRR. sPRR infusion increased plasma renin levels, renal and hepatic angiotensinogen expression, and vasopressin. Together, these results demonstrate that the deletion of adipose-PRR induced an elevation of SBP likely mediated by an intrarenal ANG II-dependent mechanism and that sPRR participates in RAS regulation and body fluid homeostasis via its capacity to activate the RAS and increase vasopressin levels. NEW & NOTEWORTHY The elevation of systolic blood pressure appears to be primarily mediated by cortical ANG II in high-fat diet-fed adipose-prorenin receptor knockout female mice. In addition, our data support a role for soluble prorenin receptor in renin-angiotensin system activation and vasopressin regulation.

Identifiants

pubmed: 30550352
doi: 10.1152/ajpheart.00473.2018
pmc: PMC6734055
doi:

Substances chimiques

Angiotensin II Type 1 Receptor Blockers 0
Antihypertensive Agents 0
Receptors, Cell Surface 0
Vasopressins 11000-17-2
Angiotensinogen 11002-13-4
Angiotensin II 11128-99-7
Losartan JMS50MPO89
Prorenin Receptor 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

H506-H515

Subventions

Organisme : NIGMS NIH HHS
ID : P20 GM103527
Pays : United States
Organisme : NIGMS NIH HHS
ID : P30 GM127211
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL142969
Pays : United States

Références

J Renin Angiotensin Aldosterone Syst. 2006 Jun;7(2):74-86
pubmed: 17083061
Hypertension. 2001 May;37(5):1199-208
pubmed: 11358929
Am J Physiol Renal Physiol. 2018 Sep 1;315(3):F521-F534
pubmed: 29667908
Hypertension. 2015 Oct;66(4):836-42
pubmed: 26303292
Int J Mol Med. 2006 Sep;18(3):483-8
pubmed: 16865234
J Hypertens. 2008 Jul;26(7):1379-89
pubmed: 18551014
J Epithel Biol Pharmacol. 2009 Jan 1;2(7):23
pubmed: 20151042
Trends Endocrinol Metab. 2014 Jun;25(6):293-302
pubmed: 24793638
Kidney Int. 2010 Nov;78(9):849-56
pubmed: 20736986
Hypertension. 2000 Mar;35(3):740-5
pubmed: 10720588
Hypertension. 2016 Jul;68(1):213-9
pubmed: 27185751
J Clin Invest. 2002 Jun;109(11):1417-27
pubmed: 12045255
Am J Physiol. 1987 Mar;252(3 Pt 2):H628-37
pubmed: 3826404
Am J Physiol Regul Integr Comp Physiol. 2011 Oct;301(4):R1067-77
pubmed: 21753145
Hypertension. 2015 Feb;65(2):352-61
pubmed: 25421983
Europace. 2009 Jun;11(6):763-9
pubmed: 19376819
Mol Cell Biol. 2012 Mar;32(6):1099-111
pubmed: 22269949
Blood Press. 1994 Jul;3(4):260-4
pubmed: 7994452
Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):E1898-906
pubmed: 26984496
PLoS One. 2017 Dec 14;12(12):e0189696
pubmed: 29240802
Dis Model Mech. 2009 Nov-Dec;2(11-12):554-62
pubmed: 19892886
J Neuroendocrinol. 2010 May;22(5):453-9
pubmed: 20163518
J Clin Hypertens (Greenwich). 2013 Jan;15(1):14-33
pubmed: 23282121
Curr Opin Nephrol Hypertens. 2018 Mar;27(2):77-82
pubmed: 29346132
J Biol Chem. 2012 Jan 2;287(1):660-71
pubmed: 22086923
FASEB J. 2014 Oct;28(10):4408-19
pubmed: 25005176
Am J Physiol Renal Physiol. 2017 Dec 1;313(6):F1243-F1253
pubmed: 28814438
Curr Hypertens Rep. 2016 Apr;18(4):29
pubmed: 26951246
Clin Exp Nephrol. 2013 Dec;17(6):848-56
pubmed: 23564382
Gend Med. 2012 Aug;9(4):287-91
pubmed: 22795464
Methods Mol Biol. 2013;1065:129-39
pubmed: 23996361
Am J Physiol Regul Integr Comp Physiol. 2013 May 15;304(10):R818-28
pubmed: 23535460
Pflugers Arch. 2017 Oct;469(10):1245-1256
pubmed: 28620832
J Am Soc Nephrol. 2002 May;13(5):1131-5
pubmed: 11960999
Hypertension. 2015 Jul;66(1):68-74
pubmed: 25941340
J Endocrinol Invest. 2011 Dec;34(11):840-6
pubmed: 21483231
Hypertension. 2012 Jun;59(6):1188-94
pubmed: 22526255
Mol Cell Endocrinol. 2015 Feb 15;402:113-9
pubmed: 25578600
Am J Physiol. 1991 Nov;261(5 Pt 2):R1118-25
pubmed: 1951759
Am J Physiol Renal Physiol. 2017 Feb 1;312(2):F245-F253
pubmed: 27122543
Hypertension. 2011 Mar;57(3):355-62
pubmed: 21282552
Hypertension. 2013 Oct;62(4):731-7
pubmed: 23959560
Am J Physiol. 1979 Sep;237(3):F232-40
pubmed: 474764
Clin J Am Soc Nephrol. 2007 Mar;2(2):196-7
pubmed: 17699405
Hypertension. 2003 May;41(5):1143-50
pubmed: 12682079
Science. 2010 Jan 22;327(5964):459-63
pubmed: 20093472
J Renin Angiotensin Aldosterone Syst. 2015 Dec;16(4):1149-58
pubmed: 25757657
Am J Physiol Renal Physiol. 2007 Aug;293(2):F526-32
pubmed: 17507604
Circ Res. 2010 Oct 1;107(7):934-8
pubmed: 20689062
J Hypertens. 2007 Dec;25(12):2441-53
pubmed: 17984666
Am J Physiol Regul Integr Comp Physiol. 2004 Oct;287(4):R943-9
pubmed: 15191907
Am J Physiol Renal Physiol. 2010 Nov;299(5):F917-28
pubmed: 20826569
Nat Med. 2013 May;19(5):557-66
pubmed: 23652116
Obesity (Silver Spring). 2014 Oct;22(10):2201-9
pubmed: 25044950
Am J Physiol Renal Physiol. 2008 Sep;295(3):F772-9
pubmed: 18579707
Curr Opin Pharmacol. 2011 Apr;11(2):180-6
pubmed: 21339086
Mol Metab. 2016 Aug 23;5(10):959-969
pubmed: 27689008
Am J Hypertens. 2015 Dec;28(12):1418-26
pubmed: 25968123
Hypertension. 2007 Feb;49(2):365-72
pubmed: 17200435
J Am Soc Nephrol. 2010 Jan;21(1):18-23
pubmed: 19917780
Cell Metab. 2011 Apr 6;13(4):469-475
pubmed: 21459331

Auteurs

Eva Gatineau (E)

Department of Pharmacology and Nutritional Sciences, University of Kentucky , Lexington, Kentucky.

Dianne M Cohn (DM)

Department of Pharmacology and Nutritional Sciences, University of Kentucky , Lexington, Kentucky.

Marko Poglitsch (M)

Attoquant Diagnostics, Vienna , Austria.

Analia S Loria (AS)

Department of Pharmacology and Nutritional Sciences, University of Kentucky , Lexington, Kentucky.

Ming Gong (M)

Department of Physiology, University of Kentucky , Lexington, Kentucky.

Frédérique Yiannikouris (F)

Department of Pharmacology and Nutritional Sciences, University of Kentucky , Lexington, Kentucky.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH